DON BROWN Founder & Chief Executive Officer, LifeOmic

Don Brown is the most successful serial software entrepreneur in the Midwest. His first company was acquired by EDS in 1986. He founded Software Artistry in 1988 which became the first software company in Indiana ever to go public and was later acquired by IBM for $200 million. Don then founded and served as CEO of Interactive Intelligence which went public in 1999 and was acquired by Genesys Telecommunications Laboratories in 2016 for $1.4 billion.

He is also an active technology and business advisor, investor, and philanthropist. In 2016, Don donated $30 million for the establishment of the Brown Immunotherapy Center at the Indiana University School of Medicine. Don received a bachelor’s in physics from Indiana University in 1978, a master’s in computer science from IU in 1982, an MD from the Indiana University School of Medicine in 1985, and a master’s in biotechnology from Johns Hopkins University in 2017.

Don is an avid outdoorsman who loves hiking, rock climbing, skiing, and snowshoeing with his eight children – especially in and around Park City, Utah. He was named Sagamore of the Wabash by Indiana Governor Mitch Daniels in 2012.



Steven Collens is CEO of MATTER, the healthcare technology incubator and innovation center. MATTER opened in February 2015 and nurtures entrepreneurs and innovators building next-generation health IT, medical device, diagnostic and biopharma technologies. MATTER works with 200 healthcare technology ventures and the company partners with 10 hospitals and health systems, five universities and more than 50 industry-leading companies. Steven is also senior advisor at Pritzker Group Venture Capital.

Prior to assuming his current role, Steven was senior vice president at Pritzker Group, the investment firm led by Tony and J.B. Pritzker. In that capacity, he led the team that created 1871, Chicago’s center for digital startups that now houses more than 400 early-stage companies. He previously worked at Abbott in a variety of domestic and international functions, including product management, policy and public affairs. In 2005, Steven helped found ConstantWellness.com to give patients control over their health data and allow healthcare providers to coordinate care of their patients. Prior to Abbott, Steven served as legislative assistant to U.S. Senator Carol Moseley-Braun.

Steven holds an MBA from Northwestern University’s Kellogg School of Management and a BA from Washington University in St. Louis. He serves on the boards of 1871, the Ann & Robert H. Lurie Children’s Hospital of Chicago, the Chicago High School for the Arts and Hubbard Street Dance Chicago. He is also a Leadership Greater Chicago fellow and a member of the Economic Club of Chicago and the Commercial Club of Chicago.


DR. JOHN E. HAMER Managing Partner, DCVBio

Dr. Hamer spent many years in Indiana, raising his two daughters here while on the Biological Science  faculty at Purdue University.  His research spanned crop diseases and fundamental aspects of cell biology and molecular signaling.  He rose to the rank of full Professor and was the recipient of several national awards including the David and Lucille Packard Fellowship,, and The National Science Foundation Presidential Faculty Fellowship.

Currently, Dr. Hamer is the Managing Partner for DCVCBio, a life science venture capital fund investing at the interface of artificial intelligence and life science product development.  Dr. Hamer has spent more than a decade in life science venture capital in the San Francisco Bay Area. He led Monsanto Growth Ventures, the VC arm of Monsanto and was a Managing Director at Burrill & Company.  Prior to his venture experience he was the CSO and later CEO of Paradigm Genetics, a leading genomics and biotechnology company that completed its IPO on NASDAQ in 2000.

Dr. Hamer contributes his time to several philanthropic boards dedicated to alleviation of poverty and hunger in the developing world including, Harvest Plus and The International Center for Tropical Agriculture.


CHRISTI L. SHAW President, Lilly Bio-Medicines + Senior Vice President, Eli Lilly and Company

Christi Shaw is a senior vice president of Eli Lilly and Company and president of Lilly Bio-Medicines. Before she rejoined Lilly in April 2017, she had most recently served as U.S. country head and president of Novartis Corporation.

Christi serves as a board member of the Biotechnology Industry Organization (BIO] and an advisor to the Healthcare Businesswomen’s Association. In 2018, Christi was honored with the Health Industry Visionary Award by the Society for Women’s Health Research. In May 2016, she was presented with Eye for Pharma’s prestigious Lifetime Achievement Award for her industry thought-leadership and dedication to the needs of patients. Also in 2016, PharmaVOICE named Shaw to its 100 Most Inspiring People list, and Diversity Journal included her on its roster of Women Worth Watching. Christi has spoken at leading industry conferences on the future of health care, driving innovation to support better patient outcomes and encouraging a diverse and inclusive culture. In addition, her perspectives have been featured in Working Mother and Life Science Leader magazines.

Christi worked at Lilly from 1989 to 2002 in sales and marketing roles, and she later held a series of increasingly responsible roles in the Janssen and Eth icon subsidiaries of Johnson & Johnson.

She earned a Bachelor of Business Administration from Iowa State University and an MBA from the University of Wisconsin. In 2017, Shaw founded the More Moments More Memories Foundation to assist people with cancer and their caregiver.


ROBERT BEECH Executive Chairman, Eccrine Systems, Inc.

Robert Beech is currently Executive Chairman of Eccrine Systems, Inc., a privately-held biotechnology company focused on advanced sweat sensors. Bob is an inventive founder, CEO and senior corporate executive with over 30 years of experience leading hi tech ventures and strategic initiatives in biotech and healthcare IT. He served as the CEO and SVP Corporate Development for Intrexon Corporation, a public biotechnology company (NYSE: XON) focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet. Bob is a co-inventor on multiple issued and pending patents related to engineered genetic materials and sweat sensing systems.

Prior to Intrexon, Bob was CEO of Digineer, Inc., an international healthcare IT software and services company he founded in 1986 and led until 2002.  Bob received a BS degree in Biology from the University of Miami. He performed post-graduate studies in microbiology at Florida State University and received a Medical Technology (M.T.) degree in conjunction with Tallahassee Memorial Regional Medical Center. Bob is a long-standing member of the American Society of Clinical Pathology and was involved in clinical diagnostics prior to leading healthcare and biotechnology ventures.

JOHN P. KANSKY President & CEO, Indiana Health Information Exchange

John P. Kansky, MSE, MBA, is the President and CEO of the Indiana Health Information Exchange. During his 11 years at IHIE, John has held roles in Strategy and Planning, Product Management, and Business Development. Prior to joining IHIE, John’s career included experience as a Healthcare IT Consultant with Health Evolutions, CIO of the Health and Hospital Corporation of Marion County (Indiana), Director of Clinical Engineering at the Indiana University Medical Center, and biomedical engineering researcher at the University of Washington School of Medicine. He is a co-inventor on three U.S. patents for diagnostic imaging technology.

John was appointed in August 2017 by the Government Accountability Office (GAO) to serve a two-year term on the Health Information Technology Advisory Committee (HITAC), which was established under the 21st Century Cures Act to provide policy recommendations to the Office of the National Coordinator for Health Information Technology (ONC).

John has spoken nationally on health information exchange (HIE) and healthcare IT. He currently serves on the Board of Directors of:

  • The Regenstrief Institute
  • Strategic HIE Collaborative (SHIEC)
  • The Sequoia Project

John is the current Chair of the Coordinating Committee of the eHealth Exchange and has served as the Vice Chair of the HIMSS North America board. He is also an adjunct professor at Indiana University in the school of Public Health. He holds a BS in Electrical Engineering from Purdue University, an MS in Bio-Engineering from the University of Washington, and an MBA from Indiana University’s Kelley School of Business.

DAN PETERSON Vice President, Industry & Government Affairs, Cook Group Incorporated

Dan Peterson is Vice President, Industry & Government Affairs for Cook Group Incorporated based in Bloomington, Indiana. Since joining Cook in 1989, Dan has held a variety of leadership roles in the areas of operations, finance, accounting and human resources. Dan’s current responsibilities involve industry, government and external affairs.  His primary areas of focus center on policies and programs in healthcare delivery as well as education, economic and workforce development.

Dan earned a BS in Biology from Indiana University in 1984 and an MBA in Finance also from Indiana University in 1989.

Dan serves on the Board of Directors for a variety of organizations throughout Indiana including BioCrossroads, Indiana Health Industry Forum, the Regional Opportunities Initiative, Inc., and the Bloomington Economic Development Corporation. Dan also serves as chairman of the South Central Regional Board of Indiana University Health, and is one of the founding board members for the Indiana Bioscience Research Institute.  Dan serves as a commission member of the Indiana Commission for Higher Education and is the immediate past chairman.

Since 1963 Cook Group companies are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. Cook Group companies employ more than 12,000 people globally with operations in North America, Europe and Asia-Pacific. Today, Cook manufactures more than 16,000 products that serve more than 40 medical specialties in 135 countries.


DR. GAVI BEGTRUP Chief Executive Officer, Eccrine Systems, Inc.

Gavi Begtrup, Ph.D. is the Chief Executive Officer of Eccrine Systems, Inc., a privately-held biotechnology company focused on advanced sweat sensors. Dr. Begtrup previously founded and was CEO of an agricultural materials startup and has supported technology commercialization and startup formation for research organizations and venture investment. Dr. Begtrup is an expert in micro- and nano-electromechanical systems, is the author of popular and scientific articles, and is an inventor on multiple issued and pending patents for novel nanoscale devices and sweat sensing system. Prior to a career in technical entrepreneurship, Dr. Begtrup was the Policy Advisor for Congresswoman Gabrielle Giffords developing legislation in oversight of NASA, DOD, and other federal agencies. He also served as science and technology policy fellow at the National Academies of Science. Dr. Begtrup received his Ph.D. in Physics from the University of California, Berkeley and his B.S. from Western Kentucky University.

DR. CHRISTINA BODUROW Retired, Senior Director of External Sourcing, Medicines Development Unit at Eli Lilly and Company

Dr. Christina (Chris) Bodurow received her B.A. from Kalamazoo College, and her Ph.D. in Organic Chemistry from Princeton University.  Chris recently retired as Senior Director of External Sourcing in the Medicines Development Unit at Eli Lilly and Company.  Some of Chris’ prior responsibilities at Lilly included Chief Operating Officer, Product Research & Development (CMC component of LRL), as well as global R&D operations leader for the Prozac and Xigris Product Teams. She is now the president and founder of PharmaDOQS, a consulting firm for drug development and R&D operations strategies and implementation. Chris has served in a number of professional and community volunteer roles, including multiple professional and trade association advisory boards for strategic sourcing, the Board of Directors of the American Chemical Society, the Chemistry Advisory Board for Princeton Chemistry, as well as the Board of Directors of the Indianapolis Symphony Orchestra.

DR. KIMBERLY K. BUHMAN Professor of Nutrition Science, Purdue University

Dr. Buhman is a Professor of Nutrition Science at Purdue University. She earned a BS in Biochemistry from Iowa State University and a PhD in Nutrition from Purdue University.  She completed post-doctoral studies at the Gladstone Institute of Cardiovascular Disease in San Francisco, CA and Washington University School of Medicine in St. Louis, MO. At Purdue, Dr. Buhman serves as Director of the Interdepartmental Graduate Program in Nutrition (INP) and is a member of the Purdue University Teaching Academy. Dr. Buhman’s research focuses on lipid metabolism with specific interests in understanding the molecular mechanisms of dietary fat absorption and dysregulation of lipid metabolism in cancer. She has authored over 50 research and review articles on these topics. The American Heart Association, American Diabetes Association, and the National Institutes of Health have funded her work. Dr. Buhman received the E.L.R. Stokstad Award for outstanding fundamental research in nutrition from the American Society for Nutrition. She is a former chair and organizer of the Federation of American Societies for Experimental Biology Science Research Conference on Intestinal Lipid Metabolism and has served as chair of the Energy and Macronutrient Metabolism Research Interest Section for the American Society for Nutrition.

DR. RUTH E. GIMENO Vice President, Diabetes Research and Clinical Investigation, Eli Lilly and Company

Dr. Gimeno leads Lilly’s efforts in diabetes and complications research. Efforts include discovering and developing next generation insulins, best-in-class incretins, and using small and large molecule approaches to identify novel therapies for diabetes and its complications, with emphasis on disease modification, cardiovascular disease, diabetic nephropathy and NASH. Dr. Gimeno has 20 years of pharmaceutical and biotechnology industry experience focused on diabetes and related metabolic disorders.

Dr. Gimeno received her undergraduate training in Medicine at the Julius-Maximilians-University in Wuerzburg, Germany, and obtained a PhD in biology from the Massachusetts Institute of Technology in Cambridge, USA. After completing her PhD, Dr. Gimeno joined Millennium Pharmaceuticals to work on novel targets for obesity and diabetes. In 2003, Dr. Gimeno moved to Wyeth (later Pfizer) in Cambridge, USA, where she continued her work in diabetes and obesity drug discovery, and also led projects in diabetic nephropathy. Dr Gimeno joined Lilly in 2011 as Chief Scientific Officer for the Diabetes Drug Hunting Team and assumed her current position in December 2016.

Dr. Gimeno’s scientific contributions include the identification and functional characterization of uncoupling protein homologs and novel lipid metabolizing enzymes, and elucidating the role and therapeutic potential of cell surface receptors and secreted proteins (eg FGF21, incretins).  Dr. Gimeno has led numerous drug discovery projects and has been involved in the clinical development of several diabetes molecules.

DR. AMELIA LINNEMANN Assistant Professor, Diabetes Group at the Herman B. Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine

Dr. Amelia Linnemann is an Assistant Professor within the Diabetes Group at the Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine. Dr. Linnemann received her PhD degree in Molecular Biology and Genetics from Wayne State University. She did postdoctoral work at the University of Wisconsin-Madison with Dr. Emery Bresnick and Dr. Dawn Belt-Davis studying hematopoietic mechanisms (including autophagy), vascular biology, inflammation, and islet biology. She was recruited as a junior faculty member to the NIH-funded Diabetes Research Center at Indiana University to develop a program in islet biology with a focus on studying pathways that link stress-induced signaling to β-cell function and survival.  Dr. Linnemann has a strong track record of discoveries in the islet biology field and is the recipient of several prestigious awards, including a K01 Career Development Award and an R03 small research grant from the National Institute of Diabetes Digestive and Kidney Diseases. Research in Dr. Linnemann’s lab is currently focused on mechanisms that enable insulin-producing pancreatic β-cells to restore homeostasis when stressed, in particular through activation of autophagy and the antioxidant response.

DR. DANIEL H. ROBERTSON Vice President of Digital Technology & Director, Applied Data Sciences Center at the Indiana Biosciences Research Institute (IBRI)

Dr. Robertson originally joined the IBRI in mid-2015 as a loaned executive from Eli Lilly and Company, but in mid-2017 he accepted a permanent position to drive innovative research among multiple life sciences companies, academic institutions and technology companies to develop solutions for critical problems. He earned his Bachelor of Science degree in chemistry, graduating Summa Cum Laude from Florida Southern College in 1986 and obtained his Ph.D. in physical chemistry from Florida State University in 1990.

After earning his Ph.D., he served as an NRC/NRL Postdoctoral Research Associate at the Naval Research Laboratory in Washington, D.C., and then held several positions at Indiana University-Purdue University Indianapolis, Ind. (IUPUI) from 1993 through 2000. In 2000, he joined Lilly as a computational research scientist. During his 17-year career there, he moved through many leadership positions, including Director of the Global Computational Chemistry and Structural Biology, and most recently, serving as Senior Director of Research IT, leading the global efforts supporting all the research IT systems and informatics in Lilly’s early drug discovery research efforts.


DR. DANILO A. TAGLE Associate Director for Special Initiatives and Acting Deputy Director, Office of the Director for the National Center for Advancing Translational Sciences and National Institutes of Health

Dan Tagle is the associate director for special initiatives at NCATS and is currently serving as the Center’s acting deputy director. He also recently served as acting director of the NCATS Office of Grants Management and Scientific Review and as executive secretary to the NCATS Advisory Council and Cures Acceleration Network Review Board. Prior to joining NCATS, Tagle was a program director for neurogenetics at the National Institute of Neurological Disorders and Stroke (NINDS), where he was involved in developing programs concerning genomics-based approaches for basic and translational research in inherited brain disorders.

Prior to joining NINDS in 2001, Tagle was an investigator and section head of molecular neurogenetics at the National Human Genome Research Institute and has been involved in the highly collaborative effort toward the positional cloning of genes for Huntington’s disease, ataxia-telangiectasia and Niemann-Pick disease type C. He has served on numerous committees and advisory boards, including the editorial boards of the journals Gene and the International Journal of Biotechnology.

Tagle obtained his Ph.D. in molecular biology and genetics from Wayne State University School of Medicine in 1990. He was an NIH National Research Service Award postdoctoral fellow in human genetics in the laboratory of Francis S. Collins, M.D., Ph.D., at the University of Michigan. Tagle has authored more than 150 scientific publications and has garnered numerous awards and patents.

KETAN PARANJAPE Vice President, Diagnostics Information Solutions, Commercial Operations, Roche Diagnostics Corporation

Ketan Paranjape heads U.S. operations for Roche’s Diagnostics Information Solutions business, whose goal is to harness the power of data, diagnostics and other critical information to support better clinical decisions. Prior to joining Roche, he was a managing director at Health2047 and VP at Akiri Networks, Silicon Valley startups funded by the American Medical Association, and at Celgene, developing and commercializing solutions for data liquidity, chronic care, productivity, security, and payments.

Ketan holds master’s degrees in electrical engineering and computer sciences from the University of Wisconsin and an MBA from the University of Oregon. He is an Honorary Research Fellow at the Imperial College London and Technical Advisor in Artificial Intelligence at Lee Kong Chian School of Medicine Singapore. He is a certified paramedic.